JP2002513417A - 血小板由来成長因子及び/又はP56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物 - Google Patents
血小板由来成長因子及び/又はP56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物Info
- Publication number
- JP2002513417A JP2002513417A JP50096499A JP50096499A JP2002513417A JP 2002513417 A JP2002513417 A JP 2002513417A JP 50096499 A JP50096499 A JP 50096499A JP 50096499 A JP50096499 A JP 50096499A JP 2002513417 A JP2002513417 A JP 2002513417A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- diethoxyquinoxaline
- amine
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/52—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/50—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
- C07D241/54—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.式I: (式中、 R1aは、適宜置換されたアルキル、ヒドロキシ、アシルオキシ、適宜置換され たアルコキシ、適宜置換されたシクロアルキルオキシ、適宜置換されたオキサヘ テロシクリルオキシ、適宜置換されたヘテロシクリルカルボニルオキシ又はハロ であり、 R1bは、水素、適宜置換されたアルキル、ヒドロキシ、アシルオキシ、適宜置 換されたアルコキシ、適宜置換されたシクロアルキルオキシ、適宜置換されたオ キサヘテロシクリルオキシ、適宜置換されたヘテロシクリルカルボニルオキシ又 はハロであり、 R1cは水素、適宜置換されたアルキル、適宜置換されたアリール、適宜置換さ れたヘテロアリール、ヒドロキシ、アシルオキシ、適宜置換されたアルコキシ、 適宜置換されたシクロアルキルオキシ、適宜置換されたヘテロシクリルオキシ、 適宜置換されたアリールオキシ、適宜置換されたヘテロアリールオキシ、適宜置 換されたヘテロシクリルカルボニルオキシ、ハロ、シアノ、R5R6N-又はアシルR5 N-であり、 R2は であり、 R3は、水素、又はオルト若しくはパラフルオロ、又はメタ低級アルキル、低級 アルコキシ、ハロ又はカルバモイルであり、 R4は、水素又は低級アルキルであり、 R5及びR6は独立して水素又はアルキルであるか、又は、R5及びR6はR5及びR6が 結合する窒素原子と一緒になってアザヘテロシクリルを形成し、 ZaはN又はCHであり、 ZbはNH又はOである。 ただし、R1a及びR1bはともに適宜置換されたアルキルではない。) で示される化合物、そのN-オキシド、水和物、溶媒和物、プロドラッグ又は塩。 2.R1aが適宜置換された低級アルコキシ、適宜置換された単環式シクロアルキ ルオキシ、適宜置換されたヘテロシクリルカルボニルオキシ又は適宜置換された 単環式オキサヘテロシクリルオキシである、請求項1記載の化合物。 3.R1aが適宜置換された低級アルコキシ又は適宜置換された単環式オキサヘテ ロシクリルオキシである、請求項2記載の化合物。 4.R1aがメトキシ、エトキシ、2-(エトキシ)エトキシ、2-(4-モルホリニル)エ トキシ又はフラニルオキシである、請求項3記載の化合物。 5.R1bが水素、適宜置換された低級アルコキシ、適宜置換された単環式シクロ アルキルオキシ、適宜置換されたヘテロシクリルカルボニルオキシ又は適宜置換 された単環式オキサヘテロシクリルオキシである、請求項1記載の化合物。 6.R1bが水素又は適宜置換された低級アルコキシである、請求項5記載の化合 物。 7.R1bがメトキシ又はエトキシである、請求項6記載の化合物。 8.R1a及びR1bが低級アルコキシである、請求項1記載の化合物。 9.R1a及びR1bがメトキシ又はエトキシである、請求項8記載の化合物。 10.R1cが水素又は適宜置換された低級アルコキシである、請求項1記載の化合 物。 11.R1cが水素、メトキシ又はエトキシである、請求項10記載の化合物。 12.R2が である、請求項1記載の化合物。 13.R2が である、請求項1記載の化合物。 14.R3が水素、オルト若しくはパラフルオロ、又はメタメチル、トリフルオロメ チル、メトキシ、フルオロ、クロロ、ブロモ又はカルバモイルである、請求項1 記載の化合物。 15.R4が水素又はメチルである、請求項1記載の化合物。 16.ZaがNである、請求項1記載の化合物。 17.ZaがCHである、請求項1記載の化合物。 18.ZbがNHである、請求項1記載の化合物。 19.ZbがOである、請求項1記載の化合物。 20.2-アニリノ-6-キノキサリノール、 2-((R)-α-メチルベンジル-アミノ)-6,7-ジエトキシキノキサリン、 2-アニリノ-6-イソプロポキシキノキサリン、 2-フェノキシ-6-メトキシキノキサリン、 (3-ブロモベンジル)-(6,7-ジメトキシキノキサリン-2-イル)-アミン、 2-(3-カルバモイルフェニルアミノ)-6-メトキシキノキサリン、 2-(2-フルオロフェニルアミノ)-6,7-ジエトキシキノキサリン、 2-(3-トリフルオロメチルフェニルアミノ)-6,7-ジエトキシキノキサリン、 フェニル-[6-(テトラヒドロフラン-3(R)-イルオキシ)キノキサリン-2-イル]アミ ン、 ベンジル-(6,7-ジメトキシキノキサリン-2-イル)-アミン、 2-((S)-α-メチルベンジル-アミノ)-6,7-ジエトキシキノキサリン、 2-ベンジルアミノ-6,7-ジエトキシキノキサリン、 (6-メトキシキノキサリン-2-イル)-(3-メチルフェニル)-アミン、 6-メトキシ-2-フェニルアミノ-キノキサリン、 2-アニリノ-6-エトキシキノキサリン、 2-(3-メトキシフェニルアミノ)-6,7-ジエトキシキノキサリン、 2-(4-フルオロフェニルアミノ)-6,7-ジエトキシキノキサリン、 6,7-ジエトキシ-2-フェノキシキノキサリン、 2-フェニルアミノ-6,7-ジエトキシキノキサリン, (6,7-ジメトキシキノキサリン-2-イル)-(3-フルオロフェニル)-アミン、 2-(3-フルオロフェニルアミノ)-6,7-ジエトキシキノキサリン、 (3-ブロモフェニル)-(6,7-ジメトキシキノキサリン-2-イル)-アミン、 (6,7-ジメトキシキノキサリン-2-イル)-フェニル-アミン、及び (3-クロロフェニル)-(6,7-ジメトキシキノキサリン-2-イル)-アミン の中から選ばれる請求項1記載の化合物、そのN-オキシド、水和物、溶媒和物、 プロドラッグ又は薬学的に許容しうる塩。 21.フェニル-[6-(テトラヒドロフラン-3(R)-イルオキシ)キノキサリン-2-イル] アミン、 ベンジル-(6,7-ジメトキシキノキサリン-2-イル)-アミン、 2-((S)-α-メチルベンジル-アミノ)-6,7-ジエトキシキノキサリン、 2-ベンジルアミノ)-6,7-ジエトキシキノキサリン、 (6-メトキシキノキサリン-2-イル)-(3-メチルフェニル)-アミン、 6-メトキシ-2-フェニルアミノ-キノキサリン、 2-アニリノ-6-エトキシキノキサリン、 2-(3-メトキシフェニルアミノ)-6,7-ジエトキシキノキサリン、 2-(4-フルオロフェニルアミノ)-6,7-ジエトキシキノキサリン、 6,7-ジエトキシ-2-フェノキシキノキサリン、 2-フェニルアミノ-6,7-ジエトキシキノキサリン、 (6,7-ジメトキシキノキサリン-2-イル)-(3-フルオロフェニル)-アミン、 2-(3-フルオロフェニルアミノ)-6,7-ジエトキシキノキサリン、 (3-ブロモフェニル)-(6,7-ジメトキシキノキサリン-2-イル)-アミン、 (6,7-ジメトキシキノキサリン-2-イル)-フェニル-アミン、及び (3-クロロフェニル)-(6,7-ジメトキシキノキサリン-2-イル)-アミン、 の中から選ばれる請求項1記載の化合物、そのN-オキシド、水和物、溶媒和物、 プロドラッグ又は薬学的に許容しうる塩。 22.フェニル-[6-(テトラヒドロフラン-3(R)-イルオキシ)キノキサリン-2-イル] アミンである、請求項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、 プロドラッグ又は薬学的に許容しうる塩。 23.ベンジル-(6,7-ジメトキシキノキサリン-2-イル)-アミンである、請求項1 記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬学的 に許容しうる塩。 24.2-((S)-α-メチルベンジル-アミノ)-6,7-ジエトキシキノキサリンである、 請求項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又 は薬学的に許容しうる塩。 25.2-ベンジルアミノ-6,7-ジエトキシキノキサリンである、請求項1記載の化 合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬学的に許容し うる塩。 26.(6-メトキシキノキサリン-2-イル)-(3-メチルフェニル)-アミンである、請 求項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は 薬学的に許容しうる塩。 27.6-メトキシ-2-フェニルアミノ-キノキサリンである、請求項1記載の化合物 又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬学的に許容しうる 塩。 28.2-アニリノ-6-エトキシキノキサリンである、請求項1記載の化合物又はそ のN-オキシド、水和物、溶媒和物、プロドラッグ又は薬学的に許容しうる塩。 29.2-(3-メトキシフェニルアミノ)-6,7-ジエトキシキノキサリンである、請求 項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬 学的に許容しうる塩。 30.2-(4-フルオロフェニルアミノ)-(6,7-ジエトキシキノキサリンである、請求 項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は 薬学的に許容しうる塩。 31.6,7-ジエトキシ-2-フェノキシキノキサリンである、請求項1記載の化合物 又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬学的に許容しうる 塩。 32.2-フェニルアミノ-6,7-ジエトキシキノキサリンである、請求項1記載の化 合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬学的に許容し うる塩。 33.(6,7-ジメトキシキノキサリン-2-イル)-(3-フルオロフェニル)-アミンであ る、請求項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッ グ又は薬学的に許容しうる塩。 34.2-(3-フルオロフェニルアミノ)-6,7-ジエトキシキノキサリンである、請求 項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬 学的に許容しうる塩。 35.(3-ブロモフェニル)-(6,7-ジメトキシキノキサリン-2-イル)-アミンである 、請求項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ 又は薬学的に許容しうる塩。 36.(6,7-ジメトキシキノキサリン-2-イル)-フェニル-アミンである、請求項1 記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又は薬学的 に許容しうる塩。 37.(3-クロロフェニル)-(6,7-ジメトキシキノキサリン-2イル)-アミンである、 請求項1記載の化合物又はそのN-オキシド、水和物、溶媒和物、プロドラッグ又 は薬学的に許容しうる塩。 38.請求項1記載の化合物及び薬学的に許容しうる担体を含む、医薬組成物。 39.請求項1記載の化合物を、PDGFチロシンキナーゼを含む組成物と接触させる 工程を含むことを特徴とする、PDGFチロシンキナーゼ活性の阻害方法。 40.請求項1記載の化合物をLckチロシンキナーゼを含む組成物と接触させる工 程を含むことを特徴とする、Lckチロシンキナーゼ活性阻害方法。 41.細胞増殖及び/又は分化及び/又はメディエータ放出によって特徴付けられ る障害を患う患者における細胞増殖、分化又はメディエータ放出の阻害方法であ って、 請求項1記載の化合物の薬学的有効量を患者に投与する工程を含むことを特徴 とする方法。 42.患者へ請求項1記載の化合物又は薬学的に許容しうる塩の薬学的有効量を投 与する工程を含むことを特徴とする、過剰増殖性障害と関連する病理に付された 患者の治療方法。 43.病理が再狭窄である、請求項42記載の方法。 44.請求項1記載の化合物又は薬学的に許容しうる塩の有効量を患者に投与する 工程を含むことを特徴する、炎症患者の治療方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86445597A | 1997-05-28 | 1997-05-28 | |
US08/864,455 | 1997-05-28 | ||
US97261497A | 1997-11-18 | 1997-11-18 | |
US08/972,614 | 1997-11-18 | ||
PCT/US1998/010999 WO1998054156A1 (en) | 1997-05-28 | 1998-05-28 | QUINOLINE AND QUINOXALINE COMPOUNDS WHICH INHIBIT PLATELET-DERIVED GROWTH FACTOR AND/OR P56lck TYROSINE KINASES |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002513417A true JP2002513417A (ja) | 2002-05-08 |
JP2002513417A5 JP2002513417A5 (ja) | 2005-12-22 |
Family
ID=27127839
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50096599A Ceased JP2002500675A (ja) | 1997-05-28 | 1998-05-28 | 血小板由来成長因子及び/又はp56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物 |
JP50096499A Ceased JP2002513417A (ja) | 1997-05-28 | 1998-05-28 | 血小板由来成長因子及び/又はP56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物 |
JP50098799A Ceased JP2002500676A (ja) | 1997-05-28 | 1998-05-28 | 血小板由来成長因子及び/又はp56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50096599A Ceased JP2002500675A (ja) | 1997-05-28 | 1998-05-28 | 血小板由来成長因子及び/又はp56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50098799A Ceased JP2002500676A (ja) | 1997-05-28 | 1998-05-28 | 血小板由来成長因子及び/又はp56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物 |
Country Status (26)
Country | Link |
---|---|
EP (3) | EP0991628B1 (ja) |
JP (3) | JP2002500675A (ja) |
KR (2) | KR100440756B1 (ja) |
CN (3) | CN1280572A (ja) |
AP (3) | AP1362A (ja) |
AT (3) | ATE493389T1 (ja) |
AU (3) | AU751188C (ja) |
BG (3) | BG64419B1 (ja) |
BR (3) | BR9809515A (ja) |
CA (3) | CA2291728A1 (ja) |
CZ (3) | CZ296845B6 (ja) |
DE (3) | DE69842151D1 (ja) |
DK (1) | DK0991628T3 (ja) |
EA (4) | EA008136B1 (ja) |
ES (1) | ES2235331T3 (ja) |
HK (1) | HK1028042A1 (ja) |
HU (2) | HUP0004807A3 (ja) |
IL (3) | IL133007A (ja) |
NO (3) | NO323720B1 (ja) |
OA (3) | OA11222A (ja) |
PL (3) | PL195552B1 (ja) |
PT (1) | PT991628E (ja) |
SI (1) | SI0991628T1 (ja) |
SK (4) | SK158099A3 (ja) |
UA (1) | UA57790C2 (ja) |
WO (3) | WO1998054156A1 (ja) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6245760B1 (en) | 1997-05-28 | 2001-06-12 | Aventis Pharmaceuticals Products, Inc | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
SK158099A3 (en) * | 1997-05-28 | 2000-06-12 | Rhone Poulenc Rorer Pharma | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6159978A (en) | 1997-05-28 | 2000-12-12 | Aventis Pharmaceuticals Product, Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
US6180632B1 (en) * | 1997-05-28 | 2001-01-30 | Aventis Pharmaceuticals Products Inc. | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
GB9904103D0 (en) | 1999-02-24 | 1999-04-14 | Zeneca Ltd | Quinoline derivatives |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
JP5000068B2 (ja) | 2000-08-11 | 2012-08-15 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | チロシンキナーゼのインヒビターとして有用な複素環化合物 |
PL209872B1 (pl) | 2002-03-27 | 2011-10-31 | Glaxo Group Ltd | Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja |
DE10237423A1 (de) * | 2002-08-16 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen |
US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
RS20060035A (en) | 2003-07-22 | 2008-08-07 | Arena Pharmaceuticals Inc., | Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto |
CN1930128A (zh) | 2004-01-16 | 2007-03-14 | 惠氏公司 | 受体酪氨酸激酶抑制剂的喹啉中间体及其合成 |
JP2010526823A (ja) | 2007-05-10 | 2010-08-05 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Pi3キナーゼ阻害物質としてのキノキサリン誘導体 |
WO2009074607A1 (en) | 2007-12-12 | 2009-06-18 | Glaxo Group Limited | Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline |
WO2009123714A2 (en) | 2008-04-02 | 2009-10-08 | Arena Pharmaceuticals, Inc. | Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor |
US9126946B2 (en) | 2008-10-28 | 2015-09-08 | Arena Pharmaceuticals, Inc. | Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto |
EP2241557A1 (de) | 2009-04-02 | 2010-10-20 | Æterna Zentaris GmbH | Chinoxalin-Derivate und deren Anwendung zur Behandlung gutartiger und bösartiger Tumorerkrankungen |
EP2473498A1 (en) | 2009-09-04 | 2012-07-11 | Bayer Pharma Aktiengesellschaft | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
CN101823998B (zh) * | 2010-05-05 | 2015-03-25 | 江苏利田科技股份有限公司 | 一种反应器耦合模拟移动床乙氧基喹啉清洁生产工艺 |
EP2624695B1 (en) | 2010-10-08 | 2015-09-23 | Nivalis Therapeutics, Inc. | Novel substituted quinoline compounds as s-nitrosoglutathione reductase inhibitors |
GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
EP2651223A4 (en) | 2010-12-16 | 2015-07-22 | Nivalis Therapeutics Inc | NOVEL BICYCLIC AROMATIC COMPOUNDS SUBSTITUTED AS INHIBITORS OF S-NITROSOGLUTATHION REDUCTASE |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
ES2605946T3 (es) | 2012-03-14 | 2017-03-17 | Bayer Intellectual Property Gmbh | Imidazopiridazinas sustituidas |
PT2841428T (pt) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Inibidores de adn-pk |
GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
PT3495367T (pt) | 2012-06-13 | 2020-11-12 | Incyte Holdings Corp | Compostos tricíclicos substituídos como inibidores de fgfr |
WO2014026125A1 (en) | 2012-08-10 | 2014-02-13 | Incyte Corporation | Pyrazine derivatives as fgfr inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
EP3985003B1 (en) | 2013-03-12 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
TWI715901B (zh) | 2013-04-19 | 2021-01-11 | 美商英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
PE20160156A1 (es) | 2013-06-11 | 2016-04-20 | Bayer Pharma AG | Derivados de prodroga de triazolpiridinas sustituidas |
CN105814036B (zh) | 2013-10-17 | 2018-10-26 | 沃泰克斯药物股份有限公司 | 作为dna-pk抑制剂的共晶 |
HUE053653T2 (hu) | 2014-03-26 | 2021-07-28 | Astex Therapeutics Ltd | FGFR inhibitor és IGF1R inhibitor kombinációi |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
EP3848034A1 (en) | 2014-03-26 | 2021-07-14 | Astex Therapeutics Limited | Cmet-inhibitors for use in delaying the emergence in resistance to fgfr inhibitors |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
CN113004278B (zh) | 2015-02-20 | 2023-07-21 | 因赛特控股公司 | 作为fgfr抑制剂的双环杂环 |
US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
CN109562085A (zh) | 2015-06-12 | 2019-04-02 | 阿速万科学有限责任公司 | 用于预防和治疗rem睡眠行为障碍的二芳基和芳基杂芳基脲衍生物 |
AU2016291673A1 (en) | 2015-07-15 | 2018-01-25 | Axovant Sciences Gmbh | Diaryl and arylheteroaryl urea derivatives for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease |
US10399946B2 (en) | 2015-09-10 | 2019-09-03 | Laurel Therapeutics Ltd. | Solid forms of an S-Nitrosoglutathione reductase inhibitor |
CN108137546B (zh) | 2015-09-23 | 2021-07-27 | 詹森药业有限公司 | 双杂芳基取代的1,4-苯并二氮杂卓化合物及其用于治疗癌症的用途 |
CA2996857C (en) | 2015-09-23 | 2024-05-21 | Janssen Pharmaceutica Nv | Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
WO2019213544A2 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Solid forms of an fgfr inhibitor and processes for preparing the same |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
TW202128685A (zh) | 2019-10-14 | 2021-08-01 | 美商英塞特公司 | 作為fgfr抑制劑之雙環雜環 |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0133244B1 (en) * | 1983-07-22 | 1990-12-05 | E.I. Du Pont De Nemours And Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
US4888427A (en) * | 1987-04-07 | 1989-12-19 | University Of Florida | Amino acids containing dihydropyridine ring systems for site-specific delivery of peptides to the brain |
GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
SG64322A1 (en) | 1991-05-10 | 1999-04-27 | Rhone Poulenc Rorer Int | Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
KR100224135B1 (ko) * | 1993-01-28 | 1999-10-15 | 다께다 구니오 | 퀴놀린 또는 퀴나졸린 유도체, 그 제조 및 용도 |
DE4426373A1 (de) * | 1994-07-26 | 1996-02-01 | Bayer Ag | 3-Substituierte Chinolin-5-carbonsäurederivate und Verfahren zu ihrer Herstellung |
DE69736642T2 (de) * | 1996-07-19 | 2007-09-20 | Takeda Pharmaceutical Co. Ltd. | Heterocyclische Verbindungen, ihre Herstellung und Verwendung |
CA2278244A1 (en) * | 1997-01-21 | 1998-07-23 | Nissan Chemical Industries, Ltd. | Industrial antimicrobial/mildew-proofing agents, algicides and antifouling agents containing n-quinoxalylanilines |
SK158099A3 (en) * | 1997-05-28 | 2000-06-12 | Rhone Poulenc Rorer Pharma | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
-
1998
- 1998-05-28 SK SK1580-99A patent/SK158099A3/sk unknown
- 1998-05-28 IL IL13300798A patent/IL133007A/xx not_active IP Right Cessation
- 1998-05-28 SI SI9830741T patent/SI0991628T1/ unknown
- 1998-05-28 BR BR9809515-3A patent/BR9809515A/pt not_active Application Discontinuation
- 1998-05-28 IL IL13300898A patent/IL133008A0/xx not_active IP Right Cessation
- 1998-05-28 CA CA002291728A patent/CA2291728A1/en not_active Abandoned
- 1998-05-28 CA CA002291750A patent/CA2291750A1/en not_active Abandoned
- 1998-05-28 DE DE69842151T patent/DE69842151D1/de not_active Expired - Lifetime
- 1998-05-28 WO PCT/US1998/010999 patent/WO1998054156A1/en active IP Right Grant
- 1998-05-28 AP APAP/P/1999/001711A patent/AP1362A/en active
- 1998-05-28 SK SK1581-99A patent/SK158199A3/sk unknown
- 1998-05-28 CN CN98806454A patent/CN1280572A/zh active Pending
- 1998-05-28 WO PCT/US1998/011036 patent/WO1998054158A1/en active IP Right Grant
- 1998-05-28 AP APAP/P/1999/001709A patent/AP1444A/en active
- 1998-05-28 PL PL98337087A patent/PL195552B1/pl not_active IP Right Cessation
- 1998-05-28 DK DK98925022T patent/DK0991628T3/da active
- 1998-05-28 ES ES98925022T patent/ES2235331T3/es not_active Expired - Lifetime
- 1998-05-28 AT AT98926129T patent/ATE493389T1/de not_active IP Right Cessation
- 1998-05-28 DE DE69842077T patent/DE69842077D1/de not_active Expired - Lifetime
- 1998-05-28 DE DE69828607T patent/DE69828607T2/de not_active Expired - Lifetime
- 1998-05-28 CZ CZ0418099A patent/CZ296845B6/cs not_active IP Right Cessation
- 1998-05-28 WO PCT/US1998/011000 patent/WO1998054157A1/en active IP Right Grant
- 1998-05-28 CZ CZ0415899A patent/CZ298521B6/cs not_active IP Right Cessation
- 1998-05-28 EP EP98925022A patent/EP0991628B1/en not_active Expired - Lifetime
- 1998-05-28 JP JP50096599A patent/JP2002500675A/ja not_active Ceased
- 1998-05-28 PL PL337086A patent/PL194980B1/pl unknown
- 1998-05-28 EP EP98925041A patent/EP1001945B1/en not_active Expired - Lifetime
- 1998-05-28 PL PL98337084A patent/PL194670B1/pl not_active IP Right Cessation
- 1998-05-28 AU AU77079/98A patent/AU751188C/en not_active Ceased
- 1998-05-28 AT AT98925041T patent/ATE500233T1/de not_active IP Right Cessation
- 1998-05-28 EA EA199901092A patent/EA008136B1/ru not_active IP Right Cessation
- 1998-05-28 UA UA99127137A patent/UA57790C2/uk unknown
- 1998-05-28 AP APAP/P/1999/001710A patent/AP1554A/en active
- 1998-05-28 HU HU0004807A patent/HUP0004807A3/hu unknown
- 1998-05-28 AT AT98925022T patent/ATE286886T1/de not_active IP Right Cessation
- 1998-05-28 BR BR9809172-7A patent/BR9809172A/pt not_active Application Discontinuation
- 1998-05-28 AU AU77062/98A patent/AU747026B2/en not_active Ceased
- 1998-05-28 JP JP50096499A patent/JP2002513417A/ja not_active Ceased
- 1998-05-28 JP JP50098799A patent/JP2002500676A/ja not_active Ceased
- 1998-05-28 PT PT98925022T patent/PT991628E/pt unknown
- 1998-05-28 CA CA002291774A patent/CA2291774A1/en not_active Abandoned
- 1998-05-28 SK SK1579-99A patent/SK157999A3/sk unknown
- 1998-05-28 HU HU0002084A patent/HUP0002084A3/hu unknown
- 1998-05-28 EP EP98926129A patent/EP1001946B1/en not_active Expired - Lifetime
- 1998-05-28 KR KR10-1999-7011036A patent/KR100440756B1/ko not_active IP Right Cessation
- 1998-05-28 CN CN98806430A patent/CN1261353A/zh active Pending
- 1998-05-28 KR KR10-1999-7010972A patent/KR100425638B1/ko not_active IP Right Cessation
- 1998-05-28 EA EA199901086A patent/EA002600B1/ru not_active IP Right Cessation
- 1998-05-28 CZ CZ0417999A patent/CZ298490B6/cs not_active IP Right Cessation
- 1998-05-28 IL IL13300998A patent/IL133009A0/xx not_active IP Right Cessation
- 1998-05-28 AU AU78037/98A patent/AU742739B2/en not_active Ceased
- 1998-05-28 EA EA199901090A patent/EA004103B1/ru not_active IP Right Cessation
- 1998-05-28 CN CNB98806538XA patent/CN1140516C/zh not_active Expired - Fee Related
- 1998-05-28 SK SK114-2005A patent/SK286084B6/sk not_active IP Right Cessation
- 1998-05-28 BR BR9809501-3A patent/BR9809501A/pt not_active Application Discontinuation
-
1999
- 1999-11-23 EA EA200100575A patent/EA007807B1/ru not_active IP Right Cessation
- 1999-11-26 NO NO19995818A patent/NO323720B1/no unknown
- 1999-11-26 NO NO19995819A patent/NO323721B1/no unknown
- 1999-11-26 NO NO19995817A patent/NO316377B1/no unknown
- 1999-11-29 OA OA9900262A patent/OA11222A/en unknown
- 1999-11-29 OA OA9900261A patent/OA11221A/en unknown
- 1999-11-29 OA OA9900260A patent/OA11264A/en unknown
- 1999-12-08 BG BG103965A patent/BG64419B1/bg unknown
- 1999-12-08 BG BG103963A patent/BG64444B1/bg unknown
- 1999-12-14 BG BG104006A patent/BG64445B1/bg unknown
-
2000
- 2000-11-23 HK HK00107502A patent/HK1028042A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2002513417A (ja) | 血小板由来成長因子及び/又はP56▲上lck▼チロシンキナーゼを阻害するキノリン及びキノキサリン化合物 | |
US6159978A (en) | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases | |
KR20010086050A (ko) | PDGF-수용체 및/또는 Lck 티로신 키나제억제제로서의 퀴놀린 및 퀴녹살린 화합물 | |
JP2002530387A (ja) | キノリン及びキノキサリン化合物 | |
KR100480360B1 (ko) | 혈소판-유도된 성장 인자 및/또는 p56lck 티로신 키나제를 억제하는 퀴놀린 및 퀴녹살린 화합물 | |
MXPA99011026A (en) | Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050527 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050527 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051021 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090303 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090603 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090713 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20090921 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091027 |